VolitionRx Limited (VNRX) Earnings Call Transcripts

VolitionRx Limited's Latest Earnings Call - Q1 FY2026

In the first quarter of fiscal year 2026, VolitionRx Limited (VNRX:US) reported a significant revenue increase to approximately $1 million, up 300% year-over-year from $0.2 million, primarily driven by deferred revenue recognition from its Nu.Q Vet agreement. Operating expenses rose to $6.3 million, reflecting severance costs and increased R&D investments, leading to a net cash used in operating activities of $5.3 million. Management did not provide revenue guidance for 2026, signaling continued unpredictability in revenue streams but expressed confidence in ongoing growth.

Reported metrics

Guidance from management

Management did not provide revenue guidance for 2026, citing the unpredictability of revenue streams but expressed confidence in continued growth.

What management said

I can add a little bit of color, Justin. So the way that Professor Evangelos has used it thus far is really in helping identify patients that might be having a flare-up. So it's a chronic condition that is kind of often lifelong, and can be under control with treatment, and then people can unfortunately experience flare. And so really, they're using the Nu.Q NETs assay to help monitor patients on an ongoing basis. Hi...

So I don't have a lot of detail on that to hand, but just suffice to say that there is a team they worked on the IVDR submission. And all of the documentation has gone alongside that. We haven't yet published some of that information that's going to be used to support the IVDR application because I myself have sight of it today. But the submission for IVDR status is ahead of schedule in terms of our IVDR application,...

What analysts pressed on

Analysts expressed concerns regarding the predictability of revenue streams and the impact of rising operating expenses on future profitability. There were questions about the timeline for significant licensing agreements and the potential for cash burn given the current operating loss.

Main topics on the call

• Revenue Growth — VolitionRx reported a revenue of approximately $1 million for Q1 2026, a substantial increase from $0.2 million in Q1 2025, marking a 300% year-over-year growth. CFO Terig Hughes stated, "This increase was primarily driv...
• Operating Expenses — Operating expenses increased to $6.3 million from $5.8 million year-over-year, attributed to severance costs and higher R&D expenditures. Hughes noted, "We continue to work on reducing our underlying operating expenses."
• Nu.Q Vet Developments — The completion of the validation of the Nu.Q Vet Cancer Test in Japan was highlighted as a key achievement, allowing for full automation in central labs. Cameron Reynolds emphasized that this "will significantly enhance ...
• Nu.Q NETs Clinical Studies — The company reported promising findings from clinical studies using Nu.Q NETs in trauma patients, with elevated nucleosome levels indicating complications. Reynolds stated, "The identification of reliable biomarkers in t...

Read the full VolitionRx Limited transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 36 VolitionRx Limited earnings call transcripts on record, spanning May 8, 2020 to August 14, 2026. Based on this history, VolitionRx Limited reports quarterly. The most recent call on file is dated August 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

VNRX

Exchange

NYSEAM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

36

First call

May 8, 2020

Most recent

August 14, 2026

Reporting cadence

quarterly